If you or someone you know is in crisis, call or text 988. In an emergency, call 911.

Medications Used in Treating Opioid and Alcohol Use Disorders

In brief

  • Federal guidance describes medication as part of care for opioid and alcohol use disorders.
  • Methadone, buprenorphine, and naltrexone act on opioid receptors in different ways.
  • Naltrexone, acamprosate, and disulfiram have distinct roles in alcohol use disorder treatment.
  • Treatment planning can include prescribing, clinical follow-up, and counseling.

Medication as part of a care plan

The U.S. Food and Drug Administration (FDA) describes opioid use disorder as a chronic medical condition. In MedlinePlus's overview, opioid use disorder means a pattern of opioid use that causes distress and gets in the way of daily life. Alcohol use disorder concerns loss of control over alcohol use and the consequences of that pattern, as the National Institute on Alcohol Abuse and Alcoholism (NIAAA) explains.

The Substance Abuse and Mental Health Services Administration (SAMHSA) treats medication as one part of a care plan that can also include counseling and other behavioral care. The National Institute on Drug Abuse (NIDA) describes medication as a first treatment approach for opioid use disorder, usually alongside some form of behavioral therapy or counseling. Which medication is used and which other services are included are clinical decisions, as SAMHSA's discussion of individualized treatment describes. The distinction between the parts of a plan matters because counseling approaches address questions about behavior, relationships, and day-to-day situations that a medication description leaves open.

How medications for opioid use disorder differ

The FDA lists methadone, buprenorphine, and long-acting naltrexone for opioid use disorder and groups them by how they act at opioid receptors. A receptor is a place on a cell where a substance can attach and change what the cell does. SAMHSA describes methadone as a full agonist, meaning it activates an opioid receptor. SAMHSA describes buprenorphine as a partial agonist, meaning it activates the receptor to a lesser degree. SAMHSA describes naltrexone as blocking the receptor. These categories describe how the medicines act in the body.

Methadone

SAMHSA describes methadone as a long-acting medicine that can ease opioid withdrawal and craving and blunt the effects of other opioids. Craving is a strong urge, while withdrawal refers to symptoms that can arise when the body is no longer exposed to a substance it has adapted to. NIDA's explanation of physical dependence describes that adaptation and the symptoms that can follow when exposure ends.

SAMHSA describes methadone treatment as individualized and part of comprehensive care with counseling and other services. In the SAMHSA description of opioid treatment programs, those additional services can include help with medical, educational, or employment needs. SAMHSA also describes how a person's history, preferences, and available services can matter when their clinician reviews the medication plan.

Buprenorphine

SAMHSA describes buprenorphine as easing withdrawal symptoms and cravings in treatment. Withdrawal symptoms and cravings are among the effects of physical dependence that the agency addresses in its overview of the medicine.

SAMHSA describes buprenorphine prescribing within a comprehensive treatment plan that includes counseling and other services. SAMHSA describes treatment length as a decision based on the individual's needs. The SAMHSA medication overview also describes the clinician's role in monitoring liver-related concerns and discussing side effects that affect the patient.

Naltrexone for opioid use disorder

SAMHSA describes naltrexone as a medicine that can diminish opioid cravings and block effects such as euphoria, a rush of pleasure, or sedation. The FDA lists the extended-release form for opioid use disorder. Extended release describes a formulation designed to release its active medicine over time. A formulation describes how a medicine is prepared, while an antagonist describes how it acts at a receptor.

SAMHSA's guidance on naltrexone discusses information a prescriber considers, including other health conditions and medicines the person is already prescribed. SAMHSA describes naltrexone in the context of a broader care plan with behavioral treatment. The prescriber's assessment accounts for the person's health as well as the effects the medicine is intended to address.

Medications for alcohol use disorder

NIAAA lists naltrexone, acamprosate, and disulfiram as medications the FDA has approved for the treatment of alcohol use disorder. NIAAA describes medications as possible components of treatment, alone or alongside behavioral treatment or mutual support. NIAAA's clinician resource describes different options for people depending on their needs, including review of an alternative when a person responds poorly to a medicine.

Naltrexone for alcohol use disorder

NIAAA describes naltrexone as blocking opioid receptors involved in the rewarding effects of alcohol. SAMHSA describes its role in reducing craving for alcohol and the amount a person drinks. The same generic name appears in guidance for different conditions. SAMHSA describes oral and extended-release forms for alcohol use disorder.

Acamprosate

NIAAA describes acamprosate as helping people maintain abstinence by acting on a system the brain uses to send chemical signals. The NIAAA account of that action discusses easing some of the discomfort that can occur as the brain adapts to the absence of alcohol. The institute lists restlessness, anxiety, and difficulty sleeping among its examples.

Disulfiram

NIAAA describes disulfiram as interfering with the body's breakdown of alcohol to support abstinence. In NIAAA's account of its mechanism, disulfiram blocks an enzyme involved in breaking down acetaldehyde, a substance the body forms as it processes alcohol. This description concerns a change in the way the body processes alcohol.

How clinicians connect prescribing and follow-up

MedlinePlus describes clinician evaluation, treatment planning, and prescribing as parts of care for alcohol use disorder. NIAAA's clinician resource discusses other professionals who can be involved in follow-up, including behavioral health practitioners. SAMHSA's medication guidance describes follow-up issues that differ by medicine, including monitoring liver concerns with buprenorphine and monitoring patients after naltrexone treatment. Prescribing gives the plan a starting point, and follow-up gives the person and the clinician a chance to discuss what is happening during care.

MedlinePlus includes support from family and friends among the forms of help that can accompany opioid use disorder treatment. Medical follow-up and conversations about daily life address different needs. A clinician may review how a person responds to a prescribed treatment, while counseling can consider how the person's life at home or at work affects their care, as NIDA's account of treatment for the whole person describes.

The distinction between ongoing treatment and an emergency response also explains why naloxone has a separate page on opioid overdose and naloxone. NIDA describes naloxone as a medicine for an acute opioid overdose. The page on finding treatment and what to ask describes public information about care, and the overview of alcohol and health gives more context on how clinicians assess alcohol use disorder.

Sources